vs

Side-by-side financial comparison of Edwards Lifesciences (EW) and NOV Inc. (NOV). Click either name above to swap in a different company.

NOV Inc. is the larger business by last-quarter revenue ($2.1B vs $1.6B, roughly 1.2× Edwards Lifesciences). Edwards Lifesciences runs the higher net margin — 23.1% vs 1.0%, a 22.1% gap on every dollar of revenue. On growth, Edwards Lifesciences posted the faster year-over-year revenue change (16.7% vs -9.9%). Over the past eight quarters, Edwards Lifesciences's revenue compounded faster (9.7% CAGR vs -3.8%).

Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the Sapien transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter.

NOV Inc., formerly National Oilwell Varco, is an American multinational corporation based in Houston, Texas. It is a worldwide provider of equipment and components used in oil and gas drilling and production operations, oilfield services, and supply chain integration services to the upstream oil and gas industry. The company conducts operations in more than 500 locations across six continents, operating through two reporting segments: Energy Equipment and Energy Products and Services.

EW vs NOV — Head-to-Head

Bigger by revenue
NOV
NOV
1.2× larger
NOV
$2.1B
$1.6B
EW
Growing faster (revenue YoY)
EW
EW
+26.6% gap
EW
16.7%
-9.9%
NOV
Higher net margin
EW
EW
22.1% more per $
EW
23.1%
1.0%
NOV
Faster 2-yr revenue CAGR
EW
EW
Annualised
EW
9.7%
-3.8%
NOV

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
EW
EW
NOV
NOV
Revenue
$1.6B
$2.1B
Net Profit
$380.7M
$20.0M
Gross Margin
78.0%
18.5%
Operating Margin
1.8%
2.3%
Net Margin
23.1%
1.0%
Revenue YoY
16.7%
-9.9%
Net Profit YoY
6.8%
-73.0%
EPS (diluted)
$0.66
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EW
EW
NOV
NOV
Q1 26
$1.6B
$2.1B
Q4 25
$1.6B
$2.3B
Q3 25
$1.6B
$2.2B
Q2 25
$1.5B
$2.2B
Q1 25
$1.4B
$2.1B
Q4 24
$1.4B
$2.3B
Q3 24
$1.4B
$2.2B
Q2 24
$1.4B
$2.2B
Net Profit
EW
EW
NOV
NOV
Q1 26
$380.7M
$20.0M
Q4 25
$91.2M
$-78.0M
Q3 25
$291.1M
$42.0M
Q2 25
$333.2M
$108.0M
Q1 25
$358.0M
$73.0M
Q4 24
$385.6M
$160.0M
Q3 24
$3.1B
$130.0M
Q2 24
$366.3M
$226.0M
Gross Margin
EW
EW
NOV
NOV
Q1 26
78.0%
18.5%
Q4 25
78.1%
20.3%
Q3 25
77.8%
18.9%
Q2 25
77.5%
20.4%
Q1 25
78.7%
21.3%
Q4 24
78.9%
21.4%
Q3 24
80.6%
21.4%
Q2 24
79.9%
26.6%
Operating Margin
EW
EW
NOV
NOV
Q1 26
1.8%
2.3%
Q4 25
9.6%
4.0%
Q3 25
19.8%
4.9%
Q2 25
26.8%
6.5%
Q1 25
27.9%
7.2%
Q4 24
22.6%
9.0%
Q3 24
25.9%
8.9%
Q2 24
26.8%
14.1%
Net Margin
EW
EW
NOV
NOV
Q1 26
23.1%
1.0%
Q4 25
5.8%
-3.4%
Q3 25
18.7%
1.9%
Q2 25
21.7%
4.9%
Q1 25
25.3%
3.5%
Q4 24
27.8%
6.9%
Q3 24
226.7%
5.9%
Q2 24
26.7%
10.2%
EPS (diluted)
EW
EW
NOV
NOV
Q1 26
$0.66
$0.05
Q4 25
$0.16
$-0.20
Q3 25
$0.50
$0.11
Q2 25
$0.56
$0.29
Q1 25
$0.61
$0.19
Q4 24
$0.65
$0.40
Q3 24
$5.13
$0.33
Q2 24
$0.61
$0.57

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EW
EW
NOV
NOV
Cash + ST InvestmentsLiquidity on hand
$1.3B
Total DebtLower is stronger
$1.7B
Stockholders' EquityBook value
Total Assets
$11.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EW
EW
NOV
NOV
Q1 26
$1.3B
Q4 25
$4.2B
$1.6B
Q3 25
$3.8B
$1.2B
Q2 25
$4.1B
$1.1B
Q1 25
$3.9B
$1.2B
Q4 24
$4.0B
$1.2B
Q3 24
$4.4B
$985.0M
Q2 24
$2.0B
$827.0M
Total Debt
EW
EW
NOV
NOV
Q1 26
$1.7B
Q4 25
$1.7B
Q3 25
$1.7B
Q2 25
$1.7B
Q1 25
$1.7B
Q4 24
$1.7B
Q3 24
$1.7B
Q2 24
$1.7B
Stockholders' Equity
EW
EW
NOV
NOV
Q1 26
Q4 25
$10.3B
$6.3B
Q3 25
$10.2B
$6.5B
Q2 25
$10.5B
$6.5B
Q1 25
$10.1B
$6.4B
Q4 24
$10.0B
$6.4B
Q3 24
$9.5B
$6.5B
Q2 24
$7.4B
$6.4B
Total Assets
EW
EW
NOV
NOV
Q1 26
$11.1B
Q4 25
$13.7B
$11.3B
Q3 25
$13.3B
$11.3B
Q2 25
$13.5B
$11.4B
Q1 25
$13.0B
$11.3B
Q4 24
$13.1B
$11.4B
Q3 24
$13.0B
$11.4B
Q2 24
$10.1B
$11.3B
Debt / Equity
EW
EW
NOV
NOV
Q1 26
Q4 25
0.27×
Q3 25
0.27×
Q2 25
0.27×
Q1 25
0.27×
Q4 24
0.27×
Q3 24
0.27×
Q2 24
0.27×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EW
EW
NOV
NOV
Operating Cash FlowLast quarter
Free Cash FlowOCF − Capex
$51.0M
FCF MarginFCF / Revenue
2.5%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$876.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EW
EW
NOV
NOV
Q1 26
Q4 25
$450.9M
$573.0M
Q3 25
$573.7M
$352.0M
Q2 25
$290.2M
$191.0M
Q1 25
$280.4M
$135.0M
Q4 24
$-127.5M
$591.0M
Q3 24
$351.8M
$359.0M
Q2 24
$371.5M
$432.0M
Free Cash Flow
EW
EW
NOV
NOV
Q1 26
$51.0M
Q4 25
$353.5M
$472.0M
Q3 25
$516.2M
$245.0M
Q2 25
$240.9M
$108.0M
Q1 25
$224.4M
$51.0M
Q4 24
$-177.3M
$473.0M
Q3 24
$299.9M
$277.0M
Q2 24
$286.1M
$350.0M
FCF Margin
EW
EW
NOV
NOV
Q1 26
2.5%
Q4 25
22.5%
20.7%
Q3 25
33.2%
11.3%
Q2 25
15.7%
4.9%
Q1 25
15.9%
2.4%
Q4 24
-12.8%
20.5%
Q3 24
22.1%
12.6%
Q2 24
20.9%
15.8%
Capex Intensity
EW
EW
NOV
NOV
Q1 26
Q4 25
6.2%
4.4%
Q3 25
3.7%
4.9%
Q2 25
3.2%
3.8%
Q1 25
4.0%
4.0%
Q4 24
3.6%
5.1%
Q3 24
3.8%
3.7%
Q2 24
6.2%
3.7%
Cash Conversion
EW
EW
NOV
NOV
Q1 26
Q4 25
4.94×
Q3 25
1.97×
8.38×
Q2 25
0.87×
1.77×
Q1 25
0.78×
1.85×
Q4 24
-0.33×
3.69×
Q3 24
0.11×
2.76×
Q2 24
1.01×
1.91×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EW
EW

Segment breakdown not available.

NOV
NOV

Energy Equipment$1.2B58%
Energy Products and Services$897.0M44%

Related Comparisons